Comparison of growth and feeding method in infants with and without genetic abnormalities after neonatal cardiac

Alyson R Pierick1, Trudy A Pierick2, Benjamin E Reinking2

  • 1Emory University School of Medicine, Department of Pediatrics, Atlanta, GA, USA.

Cardiology in the Young
|September 25, 2020
PubMed

Insights

Infants with congenital heart disease (CHD) and genetic abnormalities experience slower oral feeding post-surgery. Growth outcomes were similar, but genetic factors impact feeding progression in these high-risk infants.

Area of Science:

  • Pediatric Cardiology
  • Genetics
  • Neonatal Surgery

Background:

  • Congenital heart disease (CHD) arises from genetic and environmental factors, often causing growth delays in infants.
  • The combined impact of genetic abnormalities and CHD on infant growth requires further investigation.

Purpose of the Study:

  • To compare infant growth and feeding methods after neonatal cardiac surgery.
  • To analyze differences between infants with normal versus abnormal genetic testing.

Main Methods:

  • Retrospective chart review of neonates undergoing Risk Adjustment in Congenital Heart Surgery (RACHS) IV-VI procedures.
  • Collected anthropometric data (weight, length, head circumference) and feeding methods from birth to 6 months post-surgery.

Main Results:

  • Of 53 infants, 22 had abnormal genetic testing; 90% were discharged with supplemental tube feeds.
  • Infants with normal genetics showed a trend towards earlier oral feeding (80% at 5 months) compared to those with abnormal genetics (60%), though not statistically significant.
  • No significant differences in growth (weight, length, head circumference) were observed between groups.

Conclusions:

  • Infants with critical CHD, with or without genetic abnormalities, are prone to growth delays and require post-operative tube feeding.
  • Genetic abnormalities are associated with delayed oral feeding progression and increased reliance on tube feedings.
  • Systematic management protocols are crucial for high-risk infants with CHD and genetic abnormalities.
Abstract

Related Concept Videos